Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.
Article
PubMed
Google Scholar
Pignon JP, le Maître A, Bourhis J, MACH-NC Collaborative Group: Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys. 2007, 69 (2 Suppl): S112-S114. 10.1016/j.ijrobp.2007.04.088.
Article
PubMed
Google Scholar
Scully C, Bagan JV: Recent advances in Oral Oncology 2007: imaging, treatment and treatment outcomes. Oral Oncol. 2008, 44: 211-5. 10.1016/j.oraloncology.2008.01.006.
Article
PubMed
Google Scholar
Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA, Eastern Cooperative Oncology Group: Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005, 23: 3562-7. 10.1200/JCO.2005.01.057.
Article
CAS
PubMed
Google Scholar
Budach W, Hehr T, Budach V, Belka C, Dietz K: A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer. 2006, 6: 28-10.1186/1471-2407-6-28.
Article
PubMed Central
CAS
PubMed
Google Scholar
de Castro G, Snitcovsky IM, Gebrim EM, Leitão GM, Nadalin W, Ferraz AR, Federico MH: High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2007, 264: 1475-82. 10.1007/s00405-007-0395-9.
Article
PubMed
Google Scholar
Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS: Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 2008,
Google Scholar
Choong NW, Cohen EE: Epidermal growth factor receptor directed therapy in head and neck cancer. Crit Rev Oncol Hematol. 2006, 57: 25-43. 10.1016/j.critrevonc.2005.06.002.
Article
PubMed
Google Scholar
Harari PM, Huang S: Radiation combined with EGFR signal inhibitors: head and neck cancer focus. Semin Radiat Oncol. 2006, 16: 38-44. 10.1016/j.semradonc.2005.08.005.
Article
PubMed
Google Scholar
Le Tourneau C, Faivre S, Siu LL: Molecular targeted therapy of head and neck cancer: review and clinical development challenges. Eur J Cancer. 2007, 43: 2457-66. 10.1016/j.ejca.2007.08.016.
Article
CAS
PubMed
Google Scholar
Shirai K, O'Brien PE: Molecular targets in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol. 2007, 8: 239-51. 10.1007/s11864-007-0030-4.
Article
PubMed
Google Scholar
Dietz A, Boehm A, Mozet C, Wichmann G, Giannis A: Current aspects of targeted therapy in head and neck tumors. Eur Arch Otorhinolaryngol. 2008, 265 Suppl 1: S3-S12. 10.1007/s00405-008-0697-6.
Article
PubMed
Google Scholar
Glazer CA, Chang SS, Ha PK, Califano JA: Applying the molecular biology and epigenetics of head and neck cancer in everyday clinical practice. Oral Oncol. 2008,
Google Scholar
Langer CJ: Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008, 112: 2635-45. 10.1002/cncr.23521.
Article
CAS
PubMed
Google Scholar
Ang KK, Andratschke NH, Milas L: Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys. 2004, 58: 959-65.
Article
CAS
PubMed
Google Scholar
Rodemann HP, Dittmann K, Toulany M: Radiation-induced EGFR-signaling and control of DNA-damage repair. Int J Radiat Biol. 2007, 83: 781-91. 10.1080/09553000701769970.
Article
CAS
PubMed
Google Scholar
Kim S, Grandis JR, Rinaldo A, Takes RP, Ferlito A: Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck. 2008, 30: 667-74. 10.1002/hed.20859.
Article
PubMed
Google Scholar
Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, Humblet Y, Lopez-Pousa A, Hitt R, Vega Villegas ME, Duck L, Rosine D, Amellal N, Schueler A, Harstrick A: Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006, 24: 2866-72. 10.1200/JCO.2005.04.3547.
Article
CAS
PubMed
Google Scholar
Bernier J: Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck. Nat Clin Pract Oncol. 2008, 5: 705-13. 10.1038/ncponc1228.
Article
CAS
PubMed
Google Scholar
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008, 359: 1116-27. 10.1056/NEJMoa0802656.
Article
CAS
PubMed
Google Scholar
Teoh DC, Rodger S, Say J, Hartley A: Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer. Clin Oncol (R Coll Radiol). 2008, 20: 717-
Article
CAS
Google Scholar
Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP, Zelefsky MJ: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006, 24: 072-8.
Google Scholar
Guglin M, Cutro R, Mishkin JD: Trastuzumab-induced cardiomyopathy. J Card Fail. 2008, 14: 437-44. 10.1016/j.cardfail.2008.02.002.
Article
CAS
PubMed
Google Scholar
Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004, 22: 77-85. 10.1200/JCO.2004.06.075.
Article
CAS
PubMed
Google Scholar
Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P, Eccles SA: Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev. 2005, 24: 47-69. 10.1007/s10555-005-5047-1.
Article
CAS
PubMed
Google Scholar
Morgillo F, Bareschino MA, Bianco R, Tortora G, Ciardiello F: Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation. 2007, 75: 788-99. 10.1111/j.1432-0436.2007.00200.x.
Article
CAS
PubMed
Google Scholar
Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR: Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res. 2006, 12: 5064-73. 10.1158/1078-0432.CCR-06-0913.
Article
CAS
PubMed
Google Scholar
Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K: Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2006, 12: 4103-11. 10.1158/1078-0432.CCR-05-2404.
Article
CAS
PubMed
Google Scholar
Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA, Raben D: Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 2007, 6: 1683-91. 10.1158/1535-7163.MCT-07-0138.
Article
CAS
PubMed
Google Scholar
Haddad Y, Choi W, McConkey DJ: Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res. 2009, 15: 532-42. 10.1158/1078-0432.CCR-08-1733.
Article
PubMed Central
CAS
PubMed
Google Scholar
Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS: Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. 2007, 19: 2013-23. 10.1016/j.cellsig.2007.06.023.
Article
CAS
PubMed
Google Scholar
Schwentner I, Witsch-Baumgartner M, Sprinzl GM, Krugmann J, Tzankov A, Jank S, Zwierzina H, Loeffler-Ragg J: Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck. Head Neck. 2008, 30: 1040-4. 10.1002/hed.20831.
Article
PubMed
Google Scholar
Krause M, Baumann M: Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer Metastasis Rev. 2008, 27: 387-402. 10.1007/s10555-008-9141-z.
Article
CAS
PubMed
Google Scholar
Egloff AM, Grandis JR: Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin Oncol. 2008, 35: 286-97. 10.1053/j.seminoncol.2008.03.008.
Article
PubMed Central
CAS
PubMed
Google Scholar
Shang ZJ, Li ZB, Li JR: VEGF is up-regulated by hypoxic stimulation and related to tumour angiogenesis and severity of disease in oral squamous cell carcinoma: in vitro and in vivo studies. Int J Oral Maxillofac Surg. 2006, 35: 533-8. 10.1016/j.ijom.2005.09.006.
Article
PubMed
Google Scholar
Liang X, Yang D, Hu J, Hao X, Gao J, Mao Z: Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res. 2008, 28: 1659-66.
PubMed
Google Scholar
Fujita K, Sano D, Kimura M, Yamashita Y, Kawakami M, Ishiguro Y, Nishimura G, Matsuda H, Tsukuda M: Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma. Oncol Rep. 2007, 18: 47-51.
CAS
PubMed
Google Scholar
Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, Francis P, Cheiken R, Elting J, McNabola A, Wilkie D, Petrenciuc O, Chen EX: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 2007, 25: 3766-73. 10.1200/JCO.2006.10.2871.
Article
CAS
PubMed
Google Scholar
Sano D, Kawakami M, Fujita K, Kimura M, Yamashita Y, Ishiguro Y, Nishimura G, Matsuda H, Tsukuda M: Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep. 2007, 17: 289-95.
CAS
PubMed
Google Scholar
Gustafson DL, Frederick B, Merz AL, Raben D: Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol. 6474, 61: 179-88. 10.1007/s00280-007-0460-5.
Article
Google Scholar
Johnson FM, Saigal B, Talpaz M, Donato NJ: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res. 2005, 11: 6924-32. 10.1158/1078-0432.CCR-05-0757.
Article
CAS
PubMed
Google Scholar
Bussink J, Kogel van der AJ, Kaanders JH: Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2008, 9: 288-96. 10.1016/S1470-2045(08)70073-1.
Article
CAS
PubMed
Google Scholar
Nathan CO, Amirghahari N, Rong X, Giordano T, Sibley D, Nordberg M, Glass J, Agarwal A, Caldito G: Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res. 2007, 67: 2160-8. 10.1158/0008-5472.CAN-06-2449.
Article
CAS
PubMed
Google Scholar
Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK, Lee HY: Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res. 2006, 12: 653-61. 10.1158/1078-0432.CCR-05-1725.
Article
CAS
PubMed
Google Scholar
Jimeno A, Kulesza P, Wheelhouse J, Chan A, Zhang X, Kincaid E, Chen R, Clark DP, Forastiere A, Hidalgo M: Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer. 2007, 96: 952-9. 10.1038/sj.bjc.6603656.
Article
PubMed Central
CAS
PubMed
Google Scholar
Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS: Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol. 2006, 24: 4092-9. 10.1200/JCO.2005.05.3447.
Article
CAS
PubMed
Google Scholar
Specenier PM, Ciuleanu T, Latz JE, Musib LC, Darstein CL, Vermorken JB: Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. Cancer Chemother Pharmacol. 2008,
Google Scholar
Mazumdar A, Henderson YC, El-Naggar AK, Sen S, Clayman GL: Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck. 2008,
Google Scholar
Hao Y, Xie T, Korotcov A, Zhou Y, Pang X, Shan L, Ji H, Sridhar R, Wang P, Califano J, Gu X: Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivovia cyclooxygenase-2 and apoptotic pathways. Int J Cancer. 2008,
Google Scholar
Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C: Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Clin Cancer Res. 2008, 14: 4175-85. 10.1158/1078-0432.CCR-07-4470.
Article
CAS
PubMed
Google Scholar
Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, Yeh NT, Van Waes C: Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms. Mol Cancer Ther. 2008, 7: 1949-60. 10.1158/1535-7163.MCT-07-2046.
Article
PubMed Central
CAS
PubMed
Google Scholar
Li C, Li R, Grandis JR, Johnson DE: Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther. 2008, 7: 1647-55. 10.1158/1535-7163.MCT-07-2444.
Article
PubMed Central
CAS
PubMed
Google Scholar
Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstöttner W, Ackermann H, May A, Knecht R, Hambek M: Effect of bortezomib and cetuximab in EGF-stimulated HNSCC. Anticancer Res. 2008, 28: 2239-43.
CAS
PubMed
Google Scholar
Gillenwater AM, Zhong M, Lotan R: Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas(Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther. 2007, 6: 2967-75. 10.1158/1535-7163.MCT-04-0344.
Article
CAS
PubMed
Google Scholar
Prince ME, Ailles LE: Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol. 2008, 26: 2871-5. 10.1200/JCO.2007.15.1613.
Article
PubMed
Google Scholar
Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos J, Fernández L, Idris A, Sánchez MJ, Nieto A, Talamini R, Tavani A, Bosch FX, Reidel U, Snijders PJ, Meijer CJ, Viscidi R, Muñoz N, Franceschi S: IARC Multicenter Oral Cancer Study Group. J Natl Cancer Inst. 2003, 95: 1772-83.
Article
PubMed
Google Scholar
Lo WY, Lai CC, Hua CH, Tsai MH, Huang SY, Tsai CH, Tsai FJ: S100A8 is identified as a biomarker of HPV18-infected oral squamous cell carcinomas by suppression subtraction hybridization, clinical proteomics analysis, and immunohistochemistry staining. J Proteome Res. 2007, 6: 2143-51. 10.1021/pr060551+.
Article
CAS
PubMed
Google Scholar
Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, Kamel-Reid S, Dancey J, Siu LL, Tsao MS: Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol. 2007, 25: 2184-90. 10.1200/JCO.2006.07.6554.
Article
CAS
PubMed
Google Scholar